Corvus Pharmaceuticals, Inc. Investment Income, Net
Corvus Pharmaceuticals, Inc. (CRVS) reported Investment Income, Net of $2.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. investment income, net for the quarter ending 2026-06-30 was $2.05M, a 220.34% increase year-over-year.
- Corvus Pharmaceuticals, Inc. investment income, net for the quarter ending 2026-03-31 was $1.78M, a 239.81% increase year-over-year.
- Corvus Pharmaceuticals, Inc. investment income, net for the quarter ending 2025-12-31 was $603.00K, a 18.70% increase year-over-year.
- Corvus Pharmaceuticals, Inc. investment income, net for the quarter ending 2025-09-30 was $738.00K, a 30.39% increase year-over-year.
- Corvus Pharmaceuticals, Inc. investment income, net for fiscal 2025 was $2.50M, a 37.34% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. investment income, net for fiscal 2024 was $1.82M, a 15.15% increase from fiscal 2023.
- Corvus Pharmaceuticals, Inc. investment income, net for fiscal 2023 was $1.58M, a 142.20% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. investment income, net for fiscal 2022 was $654.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.05M 10-Q · filed 2026-08-06 | $3.83M 10-Q · filed 2026-08-06 | $4.43M derived: sum of 3 quarters · filed 2026-08-06 | $5.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.78M 10-Q · filed 2026-05-07 | $2.39M derived: sum of 2 quarters · filed 2026-05-07 | $3.13M derived: sum of 3 quarters · filed 2026-05-07 | $3.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $603.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.34M derived: sum of 2 quarters · filed 2026-03-12 | $1.98M derived: sum of 3 quarters · filed 2026-08-06 | $2.50M 10-K · filed 2026-03-12 |
| 2025-09-30 | $738.00K 10-Q · filed 2025-11-04 | $1.38M derived: sum of 2 quarters · filed 2026-08-06 | $1.90M 10-Q · filed 2025-11-04 | $2.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $639.00K 10-Q · filed 2026-08-06 | $1.16M 10-Q · filed 2026-08-06 | $1.67M derived: sum of 3 quarters · filed 2026-08-06 | $2.24M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $525.00K 10-Q · filed 2026-05-07 | $1.03M derived: sum of 2 quarters · filed 2026-05-07 | $1.60M derived: sum of 3 quarters · filed 2026-05-07 | $2.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $508.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.07M derived: sum of 2 quarters · filed 2026-03-12 | $1.51M derived: sum of 3 quarters · filed 2026-03-12 | $1.82M 10-K · filed 2026-03-12 |
| 2024-09-30 | $566.00K 10-Q · filed 2025-11-04 | $1.00M derived: sum of 2 quarters · filed 2025-11-04 | $1.32M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $434.00K 10-Q · filed 2025-08-07 | $750.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $316.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $1.58M 10-K · filed 2026-03-12 | |||
| 2022-12-31 | $654.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |